Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by retiredcopon May 26, 2021 8:32am
139 Views
Post# 33266354

RE:RE:Owen Dempsey

RE:RE:Owen Dempsey With yesterday's announcement , it seems pretty obvious the tests are moving in different directions ... Immusafe seems to be geared to an internet styled ma4keting plan for individuals that will have costomers purchasing for genuine need to know if and what immunity protection they have right up to the person that just buys because it's available.  PMN S TEST is geared to the needs of scientists and govt s that are trying to determine what is and isn't working, to plan out the attack on the virus.. and in most cases we won't even know who they are or that they are using the tests...but the money will be flowing in because there is an urgency for this information.....another investor pointed out to me the differences and it made big sense.... do we want to be in the business of selling 1 test to 1000 different individuals or do we want to be in  the business of selling 1000 tests to 1 party......which is more efficient and profitable when you consider the infrastructure and process required.....the last thing is...what regulatory approval has and is still being sought by the two tests....that could be what keeps changing the timeline on the Immusafe test rollout...
<< Previous
Bullboard Posts
Next >>